This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-11. (canceled)

12. (currently amended) A method of treatment of a human patient for cancer, comprising administering Et 743 at a dose level of ~~about~~ 500 to ~~about~~ 1650 micrograms/m^2 body surface area in cycles by intravenous infusion at intervals of about 1-6 weeks with an infusion time of about 2 to about 24 hours wherein said treatment results in a reduction in tumor size.

13. (previously presented) A method according to claim 12, wherein the Et 743 is administered with an infusion time of about 3 hours.

14. (currently amended) A method according to claim 13, wherein the Et 743 is administered at intervals of about ~~1 week~~ 3 to 4 weeks.

15. (previously presented) A method according to claim 14, wherein the Et 743 is administered at a dose level of about 1000 to about 1650 micrograms/m^2.

16. (previously presented) A method according to claim 15, wherein the patient is allowed to recover for the remainder of the cycle.

17. (previously presented) A method according to claim 16, wherein the cycle is 3 or 4 weeks.

18-23. (canceled)

24. (previously presented) A method according to claim 12, wherein the Et 743 is administered with an infusion time of about 24 hours.

25. (currently amended) A method according to claim 24, wherein the Et 743 is administered at intervals of about ~~1 week~~ 3 to 4 weeks.

26. (previously presented) A method according to claim 25, wherein the Et 743 is administered at a dose level of about 1000 to about 1500 micrograms/m^2.

27. (previously presented) A method according to claim 26, wherein the Et 743 is administered at a dose level of about 1500 micrograms/m^2.

28. (previously presented) A method according to claim 27, wherein the patient is allowed to recover for the remainder of the cycle.

29. (previously presented) A method according to claim 28, wherein the cycle is 3 or 4 weeks.

30. (previously presented) A method according to one of claims 12, 17, or 29, wherein the cancer is soft tissue sarcoma, melanoma, leiomyosarcoma, colon stromal sarcoma, gastric stromal sarcoma, osteosarcoma, liposarcoma, breast cancer, ovarian cancer, mesothelioma, or ocular melanoma.

31. (previously presented) A method according to claim 30, wherein the cancer has metastasized.

32. (previously presented) A method according to claim 30, wherein the patient has been previously treated for cancer with chemotherapy.

33. (previously presented) A method according to one of claims 12, 17, or 29, further comprising the administration of at least one additional drug.

34. (previously presented) A method according to claim 33, wherein the at least one additional drug is selected from: a) a drug with an antimitotic effect; b) an antimetabolite drug; c) an alkylating agent or nitrogen mustard; d) a drug which targets DNA; e) a drug which targets topoisomerase; f) a hormone or a hormone agonist or antagonist; g) a drug which targets signal transduction in tumor cells; h) an alkylating drug; i) a drug potentially affecting metastasis of tumors; j) a gene therapy or antisense agent; k) an antibody therapeutic; l) a bioactive compound of marine origin; m) a steroid analog; n) an anti-inflammatory drug; or o) an anti-emetic drug.

35. (previously presented) A method according to claim 33, wherein the at least one additional drug is dexamethasone.